Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789737 · ClinicalTrials.gov registry record · Phase 3
Welchol as Monotherapy for Type 2 Diabetes Mellitus
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 357
- Enrollment target
- 20
- Study locations
NCT00789737 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Daiichi Sankyo. The registered enrollment target is 357 participants, below the 2,745-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00789737, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 357 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Welchol
Study Locations (20)
California
- - Buena Park
- - Burbank
- - Chula Vista
- - Garden Grove
- - Huntington Park
- - Irvine
- - La Mirada
- - Lincoln
- - Lomita
Arizona
- - Green Valley
- - Mesa
- - Mesa
- - Tucson
- - Tucson
- - Tucson
Alabama
- - Birmingham
- - Birmingham
- - Montgomery
- - Muscle Shoals
Arkansas
- - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789737
The ClinicalTrials.gov registry entry for NCT00789737 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,745-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (87% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00789737 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00789737 about?
NCT00789737 is a clinical study titled "Welchol as Monotherapy for Type 2 Diabetes Mellitus". The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious...
What is the current status of trial NCT00789737?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 357 participants. The study started on 2009-01. Estimated completion is 2011-12.
What conditions does trial NCT00789737 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00789737?
The interventions under investigation include: Placebo (DRUG), Welchol (DRUG).
Who is sponsoring clinical trial NCT00789737?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00789737 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.